DDLAC is a non-ionic detergent / surfactant with a lactobionamide head group and a dodecyl chain.
Compound name: N-dodecylamine lactobionamide (DDLAC)
Catalogue number: DDLAC_250MG
Molec. Formula: C24H47NO11
MW: 525.6 g/mol
Percent Composition: C, 54.84; H, 9.01; N, 2.66; O, 33.48
Physical state: White powder
Purity (HPLC, 214nm): ≤95%
Retention time (RP18 HPLC)b: tR = 14.9 min
CMC: 0.25 mM
Exact mass: 525.3149
Stability: Store in <-20°C freezer for up to one year
Solubility Structure: Soluble in water (1.25mM), methanol and DMSO
CALIXAR uses a unique & custom-built approach
CALIXAR’s DDLAC is produced into a powder form and is utilized in an aqueous solution or buffer. DDLAC can be mixed with biological materials (biological membranes).
Our clients are able to use DDLAC to aid in the production of lipid detergents, mixed micelles, and protein detergent micelles. DDLAC enables clients to extract, to solubilize and to stabilize native and functional membrane proteins of high medical relevance within a solution.
DDLAC is a fairly mild detergent used to solubilize and stabilize native membrane proteins that are non-ionic. Consequently, as it is not sensitive to ionic strength or pH variations, they are ideal to extract precise membrane proteins.
Native Full-Length Proteins
CALIXAR’s DDLAC is non-ionic and therefore not sensitive to ionic concentration or pH shifts. DDLAC is well adapted to extract, to solubilize and to stabilize particular membrane proteins.
Specifically Made for Biotech
CALIXAR’s DDLAC (N-dodecylamine lactobionamide) extracts high-quality membrane proteins used for research, drug discovery and structural studies. Our DDLAC is specifically made for pharmaceutical and biotechnology companies, as well as academic teams (biochemists, structural biologists, pharmacologists, virologists) involved in the life science domains.
- Antibodies (including nanobodies, scaffold proteins, aptamers)
- Small molecules
- 3D Structures (cryoEM, XRay crystallography, NMR, SANS, SAXS)
- Drug discovery (Screening: HTS, FBDD, SBDD; Hit and lead validation)
- Antibody discovery (Immunization and display technologies)
- Clinical stage
Lactobionamide Surfactants with Hydrogenated, Perfluorinated or Hemifluorinated Tails
Lebaupain F. et al. 2006